Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 16/20 | 0.57 |
| ▸ | BRD9 | Q9H8M2 | 5/20 | 0.57 |
| ▸ | BRD4 | O60885 | 4/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.57 |
| ▸ | CA9 | Q16790 | 1/20 | 0.57 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.57 |
| ▸ | BRD1 | O95696 | 9/20 | 0.38 |
| ▸ | BRPF3 | Q9ULD4 | 5/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8556776 | 0.86 | BRPF1 (0.62) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL1119899 | 0.78 | BRPF1 (0.59) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL30873747 | 0.76 | BRPF1 (0.57) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL29213984 | 0.76 | BRPF1 (0.57) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL11743970 | 0.76 | BRPF1 (0.76) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL16932310 | 0.76 | BRPF1 (0.57) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL19231303 | 0.76 | BRPF1 (0.57) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL30538035 | 0.76 | BRPF1 (0.57) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL31743117 | 0.76 | BRPF1 (0.57) | BRPF1BRD9BRD4CA12CA9 | |
| SCHEMBL3263915 | 0.76 | BRPF1 (0.57) | BRPF1BRD9BRD4CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323993-B1 | 2,6-DIAMINO- PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8987242-B2 | Morpholinone compounds as factor IXA inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2473491-B1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MOCHIDA PHARM CO LTD (JP) | 2013-07-17 | — | — | EP | disclosed |
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | BRPF1 3834/4885BRD9 1723/4885BRD4 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.